Testing Multiple Treatments for Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with myasthenia gravis (MG) by a doctor.
- If you take MG medications, your doses must be stable (no recent changes).
- You do not have another autoimmune disease that would interfere with MG assessment.
- Your MG is not the most severe form (Class V, requiring breathing support).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.